在FLT3-ITD驱动的急性髓系白血病中,NF-κB/STAT5/miR-155网络靶向PU.1

NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

作者信息

Gerloff D, Grundler R, Wurm A A, Bräuer-Hartmann D, Katzerke C, Hartmann J-U, Madan V, Müller-Tidow C, Duyster J, Tenen D G, Niederwieser D, Behre G

机构信息

Division of Hematology and Oncology, Leipzig University Hospital, Leipzig, Germany.

Department of Internal Medicine III, Technical University Munich, Munich, Germany.

出版信息

Leukemia. 2015 Mar;29(3):535-47. doi: 10.1038/leu.2014.231. Epub 2014 Aug 5.

Abstract

Almost 30% of all acute myeloid leukemias (AML) are associated with an internal tandem duplication (ITD) in the juxtamembrane domain of FMS-like tyrosine kinase 3 receptor (FLT3). Patients with FLT3-ITD mutations tend to have a poor prognosis. MicroRNAs (miRNAs) have a pivotal role in myeloid differentiation and leukemia. MiRNA-155 (MiR-155) was found to be upregulated in FLT3-ITD-associated AMLs. In this study, we discovered that FLT3-ITD signaling induces the oncogenic miR-155. We show in vitro and in vivo that miR-155 expression is regulated by FLT3-ITD downstream targets nuclear factor-κB (p65) and signal transducer and activator of transcription 5 (STAT5). Further, we demonstrate that miR-155 targets the myeloid transcription factor PU.1. Knockdown of miR-155 or overexpression of PU.1 blocks proliferation and induces apoptosis of FLT3-ITD-associated leukemic cells. Our data demonstrate a novel network in which FLT3-ITD signaling induces oncogenic miR-155 by p65 and STAT5 in AML, thereby targeting transcription factor PU.1.

摘要

几乎30%的急性髓系白血病(AML)与FMS样酪氨酸激酶3受体(FLT3)近膜结构域的内部串联重复(ITD)相关。FLT3-ITD突变患者往往预后较差。微小RNA(miRNA)在髓系分化和白血病中起关键作用。研究发现,miRNA-155(MiR-155)在FLT3-ITD相关的AML中上调。在本研究中,我们发现FLT3-ITD信号传导可诱导致癌性MiR-155。我们在体外和体内均表明,MiR-155的表达受FLT3-ITD下游靶点核因子-κB(p65)和信号转导及转录激活因子5(STAT5)的调控。此外,我们证明MiR-155靶向髓系转录因子PU.1。敲低MiR-155或过表达PU.1可阻断FLT3-ITD相关白血病细胞的增殖并诱导其凋亡。我们的数据证明了一个新的网络,即FLT3-ITD信号传导通过p65和STAT5在AML中诱导致癌性MiR-155,从而靶向转录因子PU.1。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索